Navigation Links
Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
Date:12/13/2012

Lilly will continue to develop additional treatment options for patients with autoimmune diseases."

The decision to stop the FLEX-M study is expected to result in a fourth-quarter charge in the range of $20 million to $35 million (pre-tax), or approximately $0.02 per share (after-tax). The company's previously issued financial guidance for 2012 remains unchanged.

About the FLEX-M Study

The FLEX-M study (study BCDM) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tabalumab in patients with moderate-to-severe rheumatoid arthritis who had an inadequate response to methotrexate therapy. This pivotal registration study includes the assessment of the effect of tabalumab on structural progression.   

About BAFF and Tabalumab 

BAFF (B cell activating factor) is a cytokine that promotes B cell survival, proliferation and activation. In the presence of excess BAFF, B cells, including autoreactive B cells, are not appropriately eliminated by the immune system and may therefore contribute to the development of RA by producing autoantibodies and proinflammatory cytokines and "helping" autoreactive T cells. BAFF exists in both membrane-bound and soluble forms.

Tabalumab is a human immunoglobulin G subclass 4 (IgG4) monoclonal antibody (MAb) that inhibits both membrane-bound and soluble B cell activating factor (BAFF). Tabalumab is currently in Phase 3 development as a potential treatment for rheumatoid arthritis and systemic lupus erythematosus.

About Lilly's Autoimmune Pipeline

Tabalumab is one of three potential new medicines in late-stage clinical development for a variety of autoimmune conditions. The others are ixekizumab, an anti-IL-17 monoclonal antibody, for psoriasis and psoriatic arthritis, and baricitinib, a JAK1 and JAK2 inhibitor being developed in collaboration with Incyte Corporation, for RA, psoriasi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Provides Update on Next Steps for Solanezumab
2. Lilly to Expand Indianapolis Insulin Manufacturing Operations
3. Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles
4. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly Announces Results From Lung Cancer Study
7. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
8. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
9. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
10. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
11. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ExeGi Pharma, a company focused on developing ... that it has been granted a product license by ... (NNHPD) to sell Visbiome™ in Canada ... Claudio De Simone , MD, PhD and has ... Simone recently signed an exclusive agreement with ExeGi Pharma ...
(Date:7/1/2015)... Mass. , July 1, 2015 Boston Scientific ... discussing financial results and business highlights for the second quarter ... 8 a.m. ET. The call will be hosted ... and Dan Brennan , executive vice president and chief ... call will be available via the Boston Scientific website. Webcast ...
(Date:7/1/2015)... 1, 2015 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... chronic inflammatory disease and neurologic disorders, announced today the ... anatabine citrate, the Company,s lead compound. Results from the ... citrate can significantly inhibit the activation of inflammatory proteins ... developing this compound in a Phase 1 clinical trial ...
Breaking Medicine Technology:ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4
... 2011 Scientists at Osel Inc . and ... a new way to prevent HIV infection by genetically ... block viral transmission. Bioengineered bacteria introduced into the vaginal ... of simian HIV (SHIV) by nearly two thirds. ...
... July 18, 2011 Data from high-risk patients requiring ... nondeferrable, non-cardiac surgery show good short- and long-term clinical ... according to a study published online on the journal ... In the single-center study, patients treated with the Genous ...
Cached Medicine Technology:Scientists Use Live Bacteria to Fight HIV 2Scientists Use Live Bacteria to Fight HIV 3OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery 2OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery 3
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... AvePoint ... enabler of enterprise collaboration across platforms and devices, today announced it was named the ... its Citizen Connect Platform. The award, given out by the Government Technology Research Alliance ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... company, is announcing with their launch an intention to partner with companies that ... solutions on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined with ...
(Date:7/2/2015)... ... July 02, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today announced that it has made ... Neuper is the new General Manager at Catalent’s Schorndorf facility, which provides large ...
(Date:7/2/2015)... AL (PRWEB) , ... July 02, 2015 , ... Every year, DUI arrests and fatalities ... July may be the deadliest day of the year when it comes to being on ... “The National Highway Traffic Safety Association reports that 40% of all highway deaths between 2007 ...
(Date:7/2/2015)... ... July 02, 2015 , ... As the world becomes ... but also how they interact with products in their everyday lives. Technology can now ... security systems to home entertainment and safety, as well as making kitchen tasks simpler. ...
Breaking Medicine News(10 mins):Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2Health News:Attorney David Maloney Stresses Safety through Sobriety 2Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 2Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 3Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 4
... their health are more successful at beating one of ... The study, funded by the federal Agency for Healthcare ... hypertension an electronic personal health record that enables them ... eat in their medical record and e-mail their physicians ...
... Very young brains process memories of fear differently than more ... Feb. 6 issue of The Journal of Neuroscience . ... fear is stored and unlearned, and introduces new thinking on ... important paper raises questions that are the tip of the ...
... and within countries, researcher notes , , WEDNESDAY, Feb. ... and within European countries in the rates of stroke ... example, rates of such deaths in several countries -- ... much as seven to 14 times higher than in ...
... Baycap Inc. ("Baycap"),today announced that it has donated ... Coordt and Peter Metropoulos, directors at Baycap,are Mira Costa ... the school with top of the line equipment and ... equipment will allow Mira Costa to add a third ...
... Society for Neuroscience (SfN), the worlds largest organization ... and nervous system, today released a new document ... but not limited to, those who face,intimidation, harassment, ... The,document, Best Practices for Protecting Researchers and ...
... Feb. 6 MarketResearch.com, a leading online,provider ... of key,findings on the global market for ... research publisher MarketStrat, Inc., Making available ... Specialty Medical Beds Therapeutic Surfaces Worldwide,MarketResearch.com provides ...
Cached Medicine News:Health News:Impact of electronic personal health record on hypertension under study 2Health News:Impact of electronic personal health record on hypertension under study 3Health News:Impact of electronic personal health record on hypertension under study 4Health News:Very young found to process fear memories in unique way 2Health News:Death Rates From Cardiovascular Causes Vary Widely Across Europe 2Health News:SfN releases 'Best Practices for Protecting Researchers and Research' 2Health News:MarketResearch.com Distributes Key Findings on Global Specialty Medical Beds and Therapeutic Surfaces Market 2
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Hudson Drill hand drill....
Hudson Brace, snap lock chuck....
Binocular operation microscope with innovative mechanism for smooth operation....
Medicine Products: